R&D return on pharma investment picks up for the first time in six years,while 1,210 trials were affected by the pandemic between March and November 2020 has been saved
R&D return on pharma investment picks up for the first time in six years,while 1,210 trials were affected by the pandemic between March and November 2020
27 May 2021
- In 2020, the projected return from pharma innovation (for a cohort of 15 of the industry’s top R&D spenders) rose to 2.5 per cent, 0.9 percentage points higher than the 2019 average
- Between March - November 2020, the pandemic affected an estimated 1,210 global trials
In 2020, projected returns on investment in research and development (R&D) for a combined cohort of 15 global pharmaceutical companies was 2.5 per cent, 0.9 percentage points higher than in 2019. This is the first sign of a reversal in the declining trend seen over the past seven years, according to research by Deloitte’s Centre for Health Solutions.
The range in performance between the top performing and bottom performing companies has narrowed, however, with all but one company having an internal rate of return (IRR) below the industry weighted average cost of capital. (The weighted average cost of capital is acknowledged by most industries as the most common discounted cash flow method to derive enterprise value.)
In 2020, the cohort saw an increase in average forecast peak sales per pipeline asset (the amount of money a drug is expected to generate annually) to $421 million, from $357 million in 2019. However, the average cost to develop an asset (bring a drug to market) increased once more to $2,442 million, up $51 million compared to 2019 and a $1,115 million increase since 2013.
The increase in costs per asset is due mainly to a fall in the overall number of assets in late stage pipelines (the final stage of R&D before a drug is launched to market) which decreased from 213 in 2019 to 207 in 2020. Between 1 May 2019 and 30 April 2020, the cohort had a total of 53 assets approved, an increase from 39 in 2019.
Deloitte also commissioned analysis measuring the impact of the COVID-19 pandemic on clinical trials to investigate the likely impact on future year returns. The analysis revealed that between March and November 2020, the pandemic affected an estimated 1,210 trials across the industry. The vast majority of these (66 per cent) had delayed starts or completions; and eight per cent were terminated (permanently stopped) or withdrawn (stopped before enrolling any patients).
Colin Terry, Consulting Partner for European Life Sciences R&D at Deloitte, commented: “We are finally seeing seeds of change in the projected R&D productivity given recent progress of some novel trial designs and improvements in efficiency through the digitalisation of drug discovery and development. However, adoption continues to be experimental and not at scale across the industry, although accelerated by the COVID-19 pandemic across all stakeholders and regulators. The ‘need for speed’ has become all-encompassing alongside the realisation that development cycle times need to be reduced and new ways of working embraced to finally see the industry break the trends of the last decade.”
Neil Lesser, Principal, US Life Sciences R&D Leader at Deloitte added: “While the uptick in performance is encouraging, sustaining it will require companies to continue investing in approaches that led to this positive direction. These include expanding investments in digital technologies and data science approaches, as well as increasing the use of transformative development models. The industry’s response to the COVID-19 pandemic proved that biopharma innovation can be speeded up through creative approaches to drug development - only time will tell if this progress becomes a permanent legacy.”
Since 2010, our ‘Measuring the return from pharmaceutical innovation’ series has focused on the projected returns from the late-stage pipelines of a cohort of the 12 largest biopharma companies by 2009 R&D spend. Our five most recent reports also include an extension cohort of four mid-to-large cap companies with analysis back dated to 2013. (Two companies have merged making the original 16 move to 15.)
Throughout our analysis, we have used these two cohorts as a proxy to measure the industry’s ability to balance initial capital outlay with the cash inflows biopharma companies are projected to receive as a result of this investment. Over the past few years, however, we have seen a convergence in the performance of our original and extension cohorts and this year we are combining the two cohorts to form a ‘combined cohort’.
The research around disrupted clinical trials used material from GlobalData.
In this press release references to “Deloitte” are references to one or more of Deloitte Touche Tohmatsu Limited (“DTTL”) a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity.
Please see deloitte.com/about for a detailed description of the legal structure of DTTL and its member firms.
Deloitte LLP is a subsidiary of Deloitte NSE LLP, which is a member firm of DTTL, and is among the UK's leading professional services firms.
The information contained in this press release is correct at the time of going to press.
For more information, please visit www.deloitte.co.uk.